SARS-CoV-2 spike therapeutic antibodies in the age of variants

J Exp Med. 2021 May 3;218(5):e20210198. doi: 10.1084/jem.20210198.

Abstract

Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Aging / immunology*
  • Antibodies, Viral* / immunology
  • Antibodies, Viral* / therapeutic use
  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • COVID-19 Serotherapy
  • Humans
  • Immunization, Passive
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology*

Substances

  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2